Chemotherapy Induced Peripheral Neuropathy - Drugs In Development, 2021

July 2021 | 196 pages | ID: C3A20A28FBADEN
Global Markets Direct

Abstracts

Chemotherapy Induced Peripheral Neuropathy - Drugs In Development, 2021

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chemotherapy Induced Peripheral Neuropathy - Drugs In Development, 2021, provides an overview of the Chemotherapy Induced Peripheral Neuropathy (Toxicology) pipeline landscape.

Chemotherapy-induced peripheral neuropathy (CIPN) is a side effect of cancer treatment. Symptoms include pain, burning, tingling, constipation, muscle weakness, blood pressure changes and balance problems. Risk factors include longer duration of therapy, pre-existing neuropathy and type of chemotherapeutic agent.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chemotherapy Induced Peripheral Neuropathy - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Chemotherapy Induced Peripheral Neuropathy (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chemotherapy Induced Peripheral Neuropathy (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Chemotherapy Induced Peripheral Neuropathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 6, 9, 26 and 8 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.

Chemotherapy Induced Peripheral Neuropathy (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Chemotherapy Induced Peripheral Neuropathy (Toxicology).
• The pipeline guide reviews pipeline therapeutics for Chemotherapy Induced Peripheral Neuropathy (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Chemotherapy Induced Peripheral Neuropathy (Toxicology) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Chemotherapy Induced Peripheral Neuropathy (Toxicology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Chemotherapy Induced Peripheral Neuropathy (Toxicology)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Chemotherapy Induced Peripheral Neuropathy (Toxicology).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Chemotherapy Induced Peripheral Neuropathy (Toxicology) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Chemotherapy Induced Peripheral Neuropathy - Overview
Chemotherapy Induced Peripheral Neuropathy - Therapeutics Development
Chemotherapy Induced Peripheral Neuropathy - Therapeutics Assessment
Chemotherapy Induced Peripheral Neuropathy - Companies Involved in Therapeutics Development
Chemotherapy Induced Peripheral Neuropathy - Drug Profiles
Chemotherapy Induced Peripheral Neuropathy - Dormant Projects
Chemotherapy Induced Peripheral Neuropathy - Discontinued Products
Chemotherapy Induced Peripheral Neuropathy - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Chemotherapy Induced Peripheral Neuropathy, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Companies, 2021 (Contd..1)
Number of Products under Development by Companies, 2021 (Contd..2)
Number of Products under Development by Universities/Institutes, 2021
Products under Development by Companies, 2021
Products under Development by Companies, 2021 (Contd..1)
Products under Development by Companies, 2021 (Contd..2)
Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Target, 2021 (Contd..1)
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Mechanism of Action, 2021 (Contd..1)
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Abalone Bio Inc, 2021
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Achelios Therapeutics Inc, 2021
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Algo Therapeutix SAS, 2021
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Annji Pharmaceutical Co Ltd, 2021
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Apexian Pharmaceuticals Inc, 2021
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Aphios Corp, 2021
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Aptinyx Inc, 2021
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Asahi Kasei Pharma Corp, 2021
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Bristol-Myers Squibb Co, 2021
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Candel Therapeutics, 2021
Chemotherapy Induced Peripheral Neuropathy - Pipeline by CSPC NBP Pharmaceutical Co Ltd, 2021
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Daiichi Sankyo Co Ltd, 2021
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Disarm Therapeutics Inc, 2021
Chemotherapy Induced Peripheral Neuropathy - Pipeline by EA Pharma Co Ltd, 2021
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Egetis Therapeutics AB, 2021
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Enveric Biosciences Inc, 2021
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Exodos Life Sciences Limited Partnership, 2021
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Hoba Therapeutics ApS, 2021
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Immune Pharmaceuticals Inc, 2021
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Kineta Inc, 2021
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Kyorin Pharmaceutical Co Ltd, 2021
Chemotherapy Induced Peripheral Neuropathy - Pipeline by MAKScientific LLC, 2021
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Medifron DBT Co Ltd, 2021
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Metys Pharmaceuticals AG, 2021
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Mundipharma International Ltd, 2021
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Nanjing Aimeifei Biomedical Technology Co Ltd, 2021
Chemotherapy Induced Peripheral Neuropathy - Pipeline by NeurExo Sciences LLC, 2021
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Neuropathix Inc, 2021
Chemotherapy Induced Peripheral Neuropathy - Pipeline by NeuroTherpia Inc, 2021
Chemotherapy Induced Peripheral Neuropathy - Pipeline by OliPass Corporation, 2021
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Osmol Therapeutucs Inc, 2021
Chemotherapy Induced Peripheral Neuropathy - Pipeline by PharmatrophiX Inc, 2021
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Regulonix LLC, 2021
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Resolute Pharma Inc, 2021
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Senzer Ltd, 2021
Chemotherapy Induced Peripheral Neuropathy - Pipeline by SiteOne Therapeutics Inc, 2021
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Skye Bioscience Inc, 2021
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Sonnet BioTherapeutics Holdings Inc, 2021
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Sova Pharmaceuticals Inc, 2021
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Stealth BioTherapeutics Corp, 2021
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Synerkine Pharma BV, 2021
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Toray Industries Inc, 2021
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Trevena Inc, 2021
Chemotherapy Induced Peripheral Neuropathy - Pipeline by WEX Pharmaceuticals Inc, 2021
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Winsantor Inc, 2021
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Xgene Pharmaceutical Inc, 2021
Chemotherapy Induced Peripheral Neuropathy - Dormant Projects, 2021
Chemotherapy Induced Peripheral Neuropathy - Dormant Projects, 2021 (Contd..1)
Chemotherapy Induced Peripheral Neuropathy - Dormant Projects, 2021 (Contd..2)
Chemotherapy Induced Peripheral Neuropathy - Discontinued Products, 2021

List Of Figures

LIST OF FIGURES

Number of Products under Development for Chemotherapy Induced Peripheral Neuropathy, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Number of Products by Top 10 Targets, 2021
Number of Products by Stage and Top 10 Targets, 2021
Number of Products by Top 10 Mechanism of Actions, 2021
Number of Products by Stage and Top 10 Mechanism of Actions, 2021
Number of Products by Top 10 Routes of Administration, 2021
Number of Products by Stage and Top 10 Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021